vs

Side-by-side financial comparison of National Bank Holdings Corp (NBHC) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

Tarsus Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($151.7M vs $126.8M, roughly 1.2× National Bank Holdings Corp). National Bank Holdings Corp runs the higher net margin — 16.4% vs -5.5%, a 21.9% gap on every dollar of revenue. Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs 14.0%).

Old National Bank is an American regional bank with nearly 200 retail branches operated by Old National Bancorp and based in Chicago and Evansville, Indiana. With assets at $48.5 billion and 250 banking centers, Old National Bancorp is the largest financial services bank holding company headquartered in Indiana and one of the top 30 banking companies in the U.S. Old National Bank has locations in Illinois, Indiana, Iowa, Kentucky, Michigan, Minnesota, Tennessee, and Wisconsin.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

NBHC vs TARS — Head-to-Head

Bigger by revenue
TARS
TARS
1.2× larger
TARS
$151.7M
$126.8M
NBHC
Higher net margin
NBHC
NBHC
21.9% more per $
NBHC
16.4%
-5.5%
TARS
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
14.0%
NBHC

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
NBHC
NBHC
TARS
TARS
Revenue
$126.8M
$151.7M
Net Profit
$20.8M
$-8.4M
Gross Margin
Operating Margin
-5.3%
Net Margin
16.4%
-5.5%
Revenue YoY
128.4%
Net Profit YoY
-14.2%
63.8%
EPS (diluted)
$0.46
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NBHC
NBHC
TARS
TARS
Q1 26
$126.8M
Q4 25
$100.6M
$151.7M
Q3 25
$108.9M
$118.7M
Q2 25
$104.5M
$102.7M
Q1 25
$102.1M
$78.3M
Q4 24
$101.3M
$66.4M
Q3 24
$106.0M
$48.1M
Q2 24
$97.6M
$40.8M
Net Profit
NBHC
NBHC
TARS
TARS
Q1 26
$20.8M
Q4 25
$16.0M
$-8.4M
Q3 25
$35.3M
$-12.6M
Q2 25
$34.0M
$-20.3M
Q1 25
$24.2M
$-25.1M
Q4 24
$28.2M
$-23.1M
Q3 24
$33.1M
$-23.4M
Q2 24
$26.1M
$-33.3M
Operating Margin
NBHC
NBHC
TARS
TARS
Q1 26
Q4 25
19.0%
-5.3%
Q3 25
39.6%
-12.2%
Q2 25
39.8%
-21.6%
Q1 25
29.2%
-33.5%
Q4 24
34.3%
-36.8%
Q3 24
37.6%
-52.3%
Q2 24
32.5%
-81.6%
Net Margin
NBHC
NBHC
TARS
TARS
Q1 26
16.4%
Q4 25
15.9%
-5.5%
Q3 25
32.4%
-10.6%
Q2 25
32.6%
-19.8%
Q1 25
23.7%
-32.1%
Q4 24
27.8%
-34.8%
Q3 24
31.2%
-48.7%
Q2 24
26.8%
-81.6%
EPS (diluted)
NBHC
NBHC
TARS
TARS
Q1 26
$0.46
Q4 25
$0.42
$-0.17
Q3 25
$0.92
$-0.30
Q2 25
$0.88
$-0.48
Q1 25
$0.63
$-0.64
Q4 24
$0.72
$-0.57
Q3 24
$0.86
$-0.61
Q2 24
$0.68
$-0.88

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NBHC
NBHC
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$472.8M
$417.3M
Total DebtLower is stronger
$202.1M
$72.4M
Stockholders' EquityBook value
$1.7B
$343.4M
Total Assets
$12.6B
$562.2M
Debt / EquityLower = less leverage
0.12×
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NBHC
NBHC
TARS
TARS
Q1 26
$472.8M
Q4 25
$417.1M
$417.3M
Q3 25
$555.6M
$401.8M
Q2 25
$296.5M
$381.1M
Q1 25
$246.3M
$407.9M
Q4 24
$127.8M
$291.4M
Q3 24
$180.8M
$317.0M
Q2 24
$145.0M
$323.6M
Total Debt
NBHC
NBHC
TARS
TARS
Q1 26
$202.1M
Q4 25
$54.5M
$72.4M
Q3 25
$54.7M
$72.3M
Q2 25
$54.4M
$72.1M
Q1 25
$54.6M
$72.0M
Q4 24
$54.5M
$71.8M
Q3 24
$54.4M
$71.7M
Q2 24
$54.4M
$71.6M
Stockholders' Equity
NBHC
NBHC
TARS
TARS
Q1 26
$1.7B
Q4 25
$1.4B
$343.4M
Q3 25
$1.4B
$335.1M
Q2 25
$1.4B
$332.6M
Q1 25
$1.3B
$342.5M
Q4 24
$1.3B
$224.5M
Q3 24
$1.3B
$237.5M
Q2 24
$1.2B
$252.2M
Total Assets
NBHC
NBHC
TARS
TARS
Q1 26
$12.6B
Q4 25
$9.9B
$562.2M
Q3 25
$10.2B
$534.6M
Q2 25
$10.0B
$495.0M
Q1 25
$10.1B
$500.8M
Q4 24
$9.8B
$377.0M
Q3 24
$10.0B
$376.3M
Q2 24
$10.0B
$376.8M
Debt / Equity
NBHC
NBHC
TARS
TARS
Q1 26
0.12×
Q4 25
0.04×
0.21×
Q3 25
0.04×
0.22×
Q2 25
0.04×
0.22×
Q1 25
0.04×
0.21×
Q4 24
0.04×
0.32×
Q3 24
0.04×
0.30×
Q2 24
0.04×
0.28×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NBHC
NBHC
TARS
TARS
Operating Cash FlowLast quarter
$19.3M
Free Cash FlowOCF − Capex
$13.0M
FCF MarginFCF / Revenue
8.6%
Capex IntensityCapex / Revenue
4.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NBHC
NBHC
TARS
TARS
Q1 26
Q4 25
$162.4M
$19.3M
Q3 25
$52.4M
$18.3M
Q2 25
$32.3M
$-29.4M
Q1 25
$39.6M
$-20.7M
Q4 24
$155.3M
$-22.2M
Q3 24
$47.0M
$-8.7M
Q2 24
$31.9M
$-14.4M
Free Cash Flow
NBHC
NBHC
TARS
TARS
Q1 26
Q4 25
$13.0M
Q3 25
$16.3M
Q2 25
$-30.4M
Q1 25
$-21.2M
Q4 24
$-22.3M
Q3 24
$-8.9M
Q2 24
$-15.4M
FCF Margin
NBHC
NBHC
TARS
TARS
Q1 26
Q4 25
8.6%
Q3 25
13.8%
Q2 25
-29.6%
Q1 25
-27.1%
Q4 24
-33.5%
Q3 24
-18.6%
Q2 24
-37.8%
Capex Intensity
NBHC
NBHC
TARS
TARS
Q1 26
Q4 25
4.2%
Q3 25
1.6%
Q2 25
1.0%
Q1 25
0.8%
Q4 24
0.1%
Q3 24
0.6%
Q2 24
2.5%
Cash Conversion
NBHC
NBHC
TARS
TARS
Q1 26
Q4 25
10.13×
Q3 25
1.48×
Q2 25
0.95×
Q1 25
1.64×
Q4 24
5.51×
Q3 24
1.42×
Q2 24
1.22×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

NBHC
NBHC

Net Interest Income$108.8M86%
Noninterest Income$18.0M14%

TARS
TARS

Segment breakdown not available.

Related Comparisons